<DOC>
	<DOCNO>NCT00099554</DOCNO>
	<brief_summary>The purpose study evaluate proportion Rheumatoid Arthritis ( RA ) subject achieve `` good '' `` moderate '' DAS28 response ( EULAR28 criterion ) Week 16 etanercept 50 mg subcutaneously ( SC ) weekly patient fail infliximab .</brief_summary>
	<brief_title>Effectiveness Safety Enbrel® ( Etanercept ) Rheumatoid Arthritis Subjects Who Have Failed Remicade® ( Infliximab )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Adults RA ( ACR criterion ) great equal 6 month Infliximab treatment least 18 week Infliximab infusion prior screen increase dose regimen : 5 mg/kg every 48 week ( dose ) , OR , 3 mg/kg every 46 week ( frequency ) Failing infliximab define ALL follow screen baseline visit : Disease Activity Score ( DAS 28 ) great equal 4.5 , great equal 5 swollen joint , great equal 5 tender joint Subjects must receive stable methotrexate ( MTX ) , dose great equal 10 mg/week least 10 week prior screen Stable disease modify antirheumatic drug ( DMARD ) therapy ( include sulfasalazine , hydroxychloroquine ) , great equal 8 week prior screen Stable dose corticosteroid , less 10 mg/day great equal 4 week prior screen Stable dose nonsteroidal antiinflammatory drug ( NSAIDs ) great equal 1 week prior screen ACR functional class IV Prior treatment etanercept Receipt investigational drug/biologic within 28 day study drug initiation Active infection predisposition infection Elective surgery plan study period Intraarticular , soft tissue , intramuscular corticosteroid injection 4 week prior screen Contraindications etanercept define package insert Severe comorbidities : History cancer within 5 year ; Diagnosis class III IV congestive heart failure ( CHF ) ; Uncontrolled hypertension ( HTN ) ; CNSdemyelinating event suggestive multiple sclerosis ( MS ) ; Known HIVpositive status ; Oxygendependent pulmonary status ; Chronic hepatitis B C ; Systemic Lupus Erythematosus ( SLE ) ; Active prior history tuberculosis ( TB ) ( know exposure ) positive PPD without adequate TB prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>